ArticleJournal of medical virology2021
European multicenter evaluation of Xpert® Xpress SARS-CoV-2/Flu/RSV test.
Article in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Evaluation of the STANDARD M10 Flu/RSV/SARS-CoV-2 Fast assay for the detection of influenza A/B viruses, respiratory syncytial virus, and SARS-CoV-2 in nasopharyngeal swab specimens.Microbiology spectrum · 2026Article
- From Triplex to Quadruplex: Enhancing CDC's Respiratory qPCR Assay with RSV Detection on Panther FusionMicroorganisms · 2026Article
- Key Insights into Respiratory Virus Testing: Sensitivity and Clinical Implications.Microorganisms · 2025Review
- Article
- Gargle sample is an effective option in a novel fully automated molecular point-of-care test for influenza: a multicenter study.Virology journal · 2023Article
- Trends in Hospitalization and Mortality for Influenza and Other Respiratory Viruses during the COVID-19 Pandemic in the United States.Vaccines · 2023Article
- ONE ASSAY TO TEST THEM ALL: COMPARING MULTIPLEX ASSAYS FOR EXPANSION OF RESPIRATORY VIRUS SURVEILLANCE.medRxiv : the preprint server for health sciences · 2023Article
- One assay to test them all: Multiplex assays for expansion of respiratory virus surveillance.Frontiers in medicine · 2023Article
- Respiratory syncytial virus with ongoing COVID-19: is it an emerging threat?Annals of medicine and surgery (2012) · 2023Article
- The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review.Infection and drug resistance · 2023Review
- Characterization of viral infections in children with influenza-like-illness during December 2018-January 2019.Frontiers in cellular and infection microbiology · 2023Article
- Review
- The Future of Point-of-Care Nucleic Acid Amplification Diagnostics after COVID-19: Time to Walk the Walk.International journal of molecular sciences · 2022Review
- Impact of COVID-19 on the Changing Patterns of Respiratory Syncytial Virus Infections.Infectious disease reports · 2022Review
- Dramatic Decrease of Vitamin K2 Subtype Menaquinone-7 in COVID-19 Patients.Antioxidants (Basel, Switzerland) · 2022Article
- Influence of preanalytical parameters on influenza and respiratory syncytial virus molecular detection.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Article
- Influenza A, Influenza B, and SARS-CoV-2 Similarities and Differences - A Focus on Diagnosis.Frontiers in microbiology · 2022Review
- Increased Kynurenine Indicates a Fatal Course of COVID-19.Antioxidants (Basel, Switzerland) · 2021Article
- Multi-center evaluation of Cepheid Xpert® Xpress SARS-CoV-2/Flu/RSV molecular point-of-care test.Journal of clinical virology plus · 2021Article
- European multicenter evaluation of Xpert® Xpress SARS-CoV-2/Flu/RSV test.Journal of medical virology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are paramount for reducing the spread of the current pandemic. During additional seasonal epidemics with influenza A/B and respiratory syncytial virus (RSV), the clinical signs and symptoms cannot be distinguished easily from SARS-CoV-2. Therefore, a new assay combining four targets in the form of the new Xpert Xpress SARS-CoV-2/Flu/RSV assay was evaluated. The assay was compared to the Xpert Xpress SARS-CoV-2, Xpert Xpress Flu/RSV, Seegene Flu/RSV, influenza A/B r-gene® and RSV/hMPV r-gene®. A total of 295 nasopharyngeal and throat swabs were tested at four institutes throughout Europe including 72 samples positive for SARS-CoV-2, 65 for influenza A, 47 for influenza B, and 77 for RSV. The sensitivity of the new assay was above 95% for all targets, with the highest for SARS-CoV-2 (97.2%). The overall correlation of SARS-CoV-2 Ct values between Xpert Xpress SARS-CoV-2 assay and Xpert Xpress SARS-CoV-2/Flu/RSV assay was high. The agreement between Ct values above 30 showed the multiplex giving higher Ct values for SARS-CoV-2 on average than the singleplex assay. In conclusion, the new assay is a rapid and reliable alternative with less hands-on time for the detection of not one, but four upper respiratory tract pathogens that may circulate at the same time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.